Skip to content

Evaluation of Magnesium effects on brain tumor surgery

Comparison of magnesium sulfate infusion with placebo on prevention of brain injury in craniotomy surgery patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT201204159475N1
Enrollment
60
Registered
2013-07-16
Start date
2013-02-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neoplasm of brain. Malignant neoplasm of brain (unspecified)

Interventions

Intervention 1: 5 grams of magnesium sulfate in 1 liter of normal saline via intravenous infusion over 6 hours daily for 2 days before surgery and 5 grams of magnesium sulfate in 1 liter of normal sa
Treatment - Drugs
Placebo
5 grams of magnesium sulfate in 1 liter of normal saline via intravenous infusion over 6 hours daily for 2 days before surgery and 5 grams of magnesium sulfate in 1 liter of normal saline via intrave
Infusion of 1 liter of normal saline over 6 hours daily for 2 days before surgery and infusion of 1 liter of normal saline over 6 hours during surgery

Sponsors

Vise-Challenger of research of Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: eligible patients for brain tumor craniotomy exclusion criteria of the study: - creatinine greater than 1.5 mg / dl - Renal failure and nephrotic syndrome - Heart rate below 60 beats per minute - Severe metabolic disorders - Coagulation disorders (coagulopathy) - Myasthenia Gravis - Previous use of magnesium - Diabetes Mellitus - Age over 60 or under 18 - GCS score less than 6 - Major cardiopulmonary disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
CRP. Timepoint: before intervention, before surgery, after surgery. Method of measurement: ELISA kit.;S100b protein. Timepoint: before intervention, before surgery, after surgery. Method of measurement: ELISA kit.

Secondary

MeasureTime frame
Neurological adverse reactions. Timepoint: After surgery up to 6 month. Method of measurement: Clinical evaluation by neurosurgeon or neurologist.;Pain and bleeding during and after surgery. Timepoint: During and after surgery. Method of measurement: Clinical evaluation by anesthesiologist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Khajavi

Sina Hospital

khajavim@sins.tums.ac.ir+98 21 6670 1041

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026